USPTO serial 79435684
VITROLOGY
Reviewed by CopyMark Law Group
Status 402
- Filing date
- Status date
- Registration date
- —
- Examiner
- MALYSZEK, KIMBERLY RAY
- Law office
- TMO LAW OFFICE 122
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with VITROLOGY?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 042 | Biological, material and substance and medical device testing, analysis, research and study services; research in the fields of microbiology, molecular biology, epidemiology, immunology and biochemistry; DNA, RNA and virus analyses for scientific purposes; DNA, RNA and virus testing for scientific purposes; design of gene libraries such as collections of DNA and RNA fragments, variants or combinations of genes, of chemical nature or for medical use; testing, analysis and evaluation of the goods and services of others for the purpose of certification; biochemistry research, testing, inspection and analysis services for use in the field of biological material and substances and medical devices; industrial design services; conducting and creating project studies for use in the field of biological, material and substance and medical device testing and analysis; biological, material and substance structural characterization services in the field of biological material and substance and medical device testing and analysis; production monitoring in the field of biological material and substance and medical device testing and analysis; environmental surveys; scientific research, testing, inspection and analysis services in the field of pre-clinical, clinical and production cell banks, virus seeds and batch release; testing of monoclonal antibodies, proteins and recombinant proteins, viral and bacterial vaccines and cell therapies, gene therapy vectors and other biopharmaceutical products intended for human and veterinary administration; quality control of biological manufacturing testing; virology services; viral clearance chromatography services; cell culture based assays and cell culture research, testing, inspection and analysis services; in-vitro adventitious virus assays, retrovirus assays and retrovirus research, testing, inspection and analysis services; cell line characterization services (including, but not restricted to, validation and development of assays and methods and characterization of cell banks or batches or products derived from cell lines, of human or animal origin); animal-product-derived virus detection testing and services; testing and screening services for infectious contaminants in virus/vaccine vectors; services in the field of molecular biology, including validation and development of assay and testing services; quantitative Polymerase Chain Reaction (qPCR) testing services for both pre-clinical and clinical requirements; species-specific virus detection services by qPCR including, but not restricted to, human, simian, insect, murine, avian, chicken, duck, equine, bovine and porcine viruses; patient monitoring and biodistribution study services; identity, purity and stability assay and testing services, including microbial identity and genetic stability of cell lines; isoenzyme assay and DNA fingerprinting services; electron microscopy services, including, but not restricted to, transmission electron microscopy and virus particle detection and quantification; microbiology services including sterility, mycoplasma and mycobacteria culture-based assay and testing services; biosafety services; clinical trials; laboratory services; laboratory testing; laboratory analysis; research and development services relating to vaccines; product safety testing; biological analysis; biomedical testing services; biomedical research services; consultancy services and preparation of reports in connection with the aforesaid services; safety testing of pharmaceutical products and vaccines | SECTION 70 - CANCELLED | — |
| 045 | Regulatory compliance auditing; Regulatory compliance consulting of products manufactured by pharmaceutical and biotechnology industries; legal and regulatory compliance auditing services; provision of legal information and legal advice relating to laws and regulations in the field of quality, safety and performance; legal advice and consultancy relating to obtaining regulatory or governmental approvals; advisory and consultancy services in the field of obtaining regulatory and governmental approvals | SECTION 70 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Aug 13, 2026 | DETH | DEATH OF INTERNATIONAL REGISTRATION | — |
| Jul 31, 2026 | MAB2 | ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Jul 31, 2026 | ABN2 | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Mar 4, 2026 | DOCK | ASSIGNED TO EXAMINER | — |
| Feb 5, 2026 | RFNT | REFUSAL PROCESSED BY IB | — |
| Jan 29, 2026 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Jan 16, 2026 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Jan 16, 2026 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Dec 10, 2025 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Dec 9, 2025 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 9, 2025 | DOCK | ASSIGNED TO EXAMINER | — |
| Nov 3, 2025 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Nov 3, 2025 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Oct 30, 2025 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |